al-Timimi A, Buckley C H, Fox H
Department of Pathology, University of Manchester, England.
Int J Gynecol Pathol. 1985;4(1):24-41. doi: 10.1097/00004347-198501000-00003.
An immunocytochemical double horseradish peroxidase-anti-horseradish peroxidase (PAP) technique has been developed for localising estrogen, testosterone, and progesterone binding sites in normal ovaries and in epithelial ovarian neoplasms. Estrogen binding sites were present in 45% of normal ovaries, in 45% of benign epithelial neoplasms, and in 58.5% of ovarian adenocarcinomas. The equivalent figures for progesterone binding sites were 49%, 65%, and 45.2%, whilst those for testosterone binding sites were 43%, 40%, and 60.5%. Steroid binding was related neither to the grade of malignancy in epithelial neoplasms nor to the presence of metastases in cases of ovarian adenocarcinomas. The simultaneous presence of both estrogen and progesterone binding sites or of both estrogen and testosterone binding sites in ovarian adenocarcinomas was, however, associated with good differentiation. Evidence is presented to suggest that the binding sites demonstrated were specific, and it is suggested that the immunohistochemical demonstration of sex steroid hormone binding capacities in ovarian adenocarcinomas may be of value as a predictive marker for response to hormonal therapy.
已开发出一种免疫细胞化学双辣根过氧化物酶 - 抗辣根过氧化物酶(PAP)技术,用于定位正常卵巢和卵巢上皮性肿瘤中的雌激素、睾酮和孕酮结合位点。雌激素结合位点在45%的正常卵巢、45%的良性上皮性肿瘤以及58.5%的卵巢腺癌中存在。孕酮结合位点的相应数字分别为49%、65%和45.2%,而睾酮结合位点的相应数字分别为43%、40%和60.5%。类固醇结合与上皮性肿瘤的恶性程度无关,也与卵巢腺癌病例中的转移情况无关。然而,卵巢腺癌中同时存在雌激素和孕酮结合位点或雌激素和睾酮结合位点与良好分化相关。有证据表明所显示的结合位点是特异性的,并且有人提出卵巢腺癌中性类固醇激素结合能力的免疫组织化学显示可能作为激素治疗反应的预测标志物具有价值。